Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System

ANN ARBOR, Mich., July 24 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced that it has initiated a Phase II Clinical Trial for the Anaconda(TM) AAA (Abdominal Aortic Aneurysm) Stent Graft System in the U.S. The Anaconda system is manufactured by Scotland-based Terumo subs...

Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe , according to Millennium Research Group WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vasc...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

NATICK, Mass., May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disea...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease

NATICK, Mass. and BARCELONA, Spain, May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that percutaneous coronary ...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are pros...

AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents

ROCKVILLE, Md., March 28 /PRNewswire-USNewswire/ -- Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new stu...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinic...

Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use

Nearly 150,000 PCIs Were Performed on AMI Patients in 2008, According to Millennium Research Group WALTHAM, Mass., Feb. 18 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will conti...

MGuard(TM) Coronary Stent System Approved in Israel

TEL AVIV, Israel, December 8 /PRNewswire/ -- InspireMD, Ltd. announced that the MGuard(TM) coronary stent system has been approved for use in Israel by the Israeli Ministry of Health. The MGuard(TM) stent system presents a novel combination of a coronary stent merged with an embolic protec...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis ...

12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions

'New Class' of Stent with Polyzene(R)-F Surface Treatment Maximizes Endothelialization; Reduces Restenosis, Thrombogenicity, Need for Long-Term Dual Antiplatelet Therapy WASHINGTON, Oct. 13 /PRNewswire/ -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" sessio...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program

NATICK, Mass. and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS(R) Express2(TM) Pac...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

NATICK, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) sci...

TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System

PLEASANTON, Calif., Oct. 10 /PRNewswire/ -- TriReme Medical Inc. (TMI) announced today that it has been authorized to affix the CE (Conformite Europeenne) marking and commercialize in Europe the Antares(TM) Coronary Stent System, a unique main vessel stent system specially designed for use at ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today f...

Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents

Provides the Optimal Combination of Scaffolding, Deliverability and Conformability TEL AVIV, Israel, May 12 /PRNewswire/ -- Medinol is proud to announce that it has received CE Mark for its Presillion(TM) CoCr Coronary Stent, enabling physicians to treat coronary ...

Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

SPIRIT III Results Demonstrate Superior Reduction in In-Segment Late Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE with XIENCE V Compared to TAXUS ABBOTT PARK, Ill., April 22 /PRNewswire-FirstCall/ -- A study published in today's Journal of the A...

TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials

NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomized clinical trials. The analysis compared the safety and efficacy of the TAXUS(R) Expr...

Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed favorable outcomes of one- year data from the Com...

Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V - CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out t...

Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms

At two years, Company's TAXUS(R) and PROMUS(TM) Stents demonstrate positive and similar outcomes NATICK, Mass. and CHICAGO, March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed positive two-year results from Abbott's prospective, ...

TRITON-TIMI 38 Stent Analysis Favors Prasugrel

Regardless of stent timing and type, prasugrel bests clopidogrel CHICAGO, March 29 /PRNewswire/ -- Prasugrel has been shown to block platelet activity in patients with acute coronary syndromes (ACS) more effectively than clopidogrel, and to cut by more than half the risk of thrombosis, or ...

TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coro...

Study Finds Repeated Episodes of Stent Thrombosis Common

Treating stent thrombosis with another stent hikes the risk of repeat blood clotting CHICAGO, March 29 /PRNewswire/ -- When a clot develops inside a coronary stent, it can block blood flow to the heart, potentially causing a heart attack or even death. A single inc...

CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F

ATLANTA, Jan. 20 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Poly...

CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

Preclinical Studies of Valecor Platinum(TM) Coronary Stent System Indicate Positive Results and Improvements Compared to Market-Leading Bare Stent BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary...

Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent NATICK, Mass., and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced five-year and final follow- up data fro...

Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions

TAXUS ATLAS studies also reinforce deliverability of TAXUS(R) Liberte(R) drug-eluting stent in long lesions and small vessels NATICK, Mass. and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced nine-month data from the pivotal TA...

Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome

3,000 Patient Multi-center IVUS Sub-study Part of the Cardiovascular Research Foundation's ADAPT-DES Study to Quantify Causes and Cures of Drug Eluting Stent Thrombosis SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ) [TCT Booth #2013 ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical Results with XIENCE V WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically signifi...

Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis

WASHINGTON, Oct. 22 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day...

Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease

WASHINGTON, Oct. 22 /PRNewswire/ -- Patient enrollment is complete in the first randomized, prospective, multicenter trial that will compare the clinical outcomes and cost-effectiveness of a physiologic-guided percutaneous coronary intervention (PCI) strategy to an angiographic-guided one in p...

XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System

No New MACE, Zero Late Stent Thrombosis - Company Also Provides Clinical Program Update and Will Host Webcast Mon., Oct. 22 at 7:00 a.m. ET - WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow...

Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007

NATICK, Mass., Oct. 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) sc...

Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore

New Treatment Could Benefit Millions Who Suffer From Condition NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Med...

Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

HERCULES Trial Aims to Treat Renal Artery Obstructions and Lower Blood Pressure in Patients Not Responding to Medication ABBOTT PARK, Ill., Sept. 25 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced enrollment of the first patient in HERCULES (Herculink Elite Cobalt Chrom...

Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

VIENNA, Austria, Sept. 5 /PRNewswire/ -- Four analyses of three-year follow-up data showed that the CYPHER(R) Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease). The a...

TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women

NATICK, Mass. and VIENNA, Austria, Sept. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from the TAXUS WOMAN study, a gender specific analysis of the TAXUS II, IV, V and VI trials assessing the efficacy data of the TAXUS(R) paclitaxel-eluting co...

Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 mon...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

While no significant differences were found, results showed CYPHER(R) Stent had lower mortality and heart attack rates VIENNA, Austria, Sept. 4 /PRNewswire/ -- A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER(R) Sirolimus...